VBI Vaccines, Inc. (VBIV) Company Gross Revenue

Corporate emblem and logo of VBI Vaccines Inc (VBIV)

VBI Vaccines Inc. relies on global sales of hepatitis B vaccines, which ensures steady operating income. The company's sales growth rate confirms this stability, where 0.01 forms the current metric value. Innovations in virus-like particles enhance protection against COVID-19, although high market competition necessitates cost optimization to maintain the development pace of the portfolio.

VBIV - VBI Vaccines Inc. Revenue and Sales Volume over the range 07/04/2022 - 08/17/2024

Analytical breakdowns for vbivaccines.com (VBIV)

- price and consensus price forecast:
General company analysis:VBI Vaccines
Manufactured product of VBI Vaccines Inc.

Professional selection of resilient assets is based on filtering market noise to identify real cash flow dynamics and assess business scalability. By analyzing the overall sales level of VBI Vaccines Inc. (VBIV), an investor can see the rollout rates of hepatitis B vaccines and the volume of partnership grants, where stable growth confirms the expansion of VBI Vaccines Inc. (VBIV) within the biopharmaceutical market without compromising operational efficiency.